Fomivirsen

SENSORY ORGANS

Key facts

Fomivirsen is a drug catalogued in DrugCentral. It was first approved by the FDA in 1998. DrugCentral lists 1 molecular target, including UL123. Recorded indications include Cytomegaloviral retinitis.

• Molecular targets: UL123 (1 listed in DrugCentral).
• Indications: Cytomegaloviral retinitis.
• ATC code: S01AD08 (Antivirals).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Cytomegaloviral retinitis

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Immediate early protein IE1 mRNA	UL123	other	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1998-08-26	FDA	—	NOVARTIS

ATC classification

ATC code	Therapeutic hierarchy
S01AD08	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antivirals

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 160369-77-7
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fomivirsen used for?

DrugCentral lists the following indications for Fomivirsen: Cytomegaloviral retinitis.

How does Fomivirsen work?

Its molecular targets in DrugCentral include UL123.

When was Fomivirsen first approved?

Fomivirsen was first approved by the FDA in 1998.

Sources

• DrugCentral drug card 4751 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201512 — compound record and bioactivity
• DrugBank DB06759 — drug record
• FDA UNII QX5LK7YCHV — substance identity
• DailyMed: FDA labels for Fomivirsen — current prescribing information (label search)

How this page is built: methodology · editorial policy & corrections.